This is a working overview of acetylated peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-13 and is reviewed periodically as new material appears.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilised powder | Sealed vial; reconstituted before laboratory use |
| Appearance | White to off-white solid | Visual descriptor used on certificates of analysis |
| Solubility class | Water-soluble | Dissolves in water and aqueous buffers |
| Reported mass, fragment | Near 889 Da | Value depends on the stated sequence |
| Reported mass, parent protein | Near 4963 Da | 43-residue thymosin beta-4 |
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
These capabilities enable investigators to translate large-scale observational data into evidence that informs clinical practice, community interventions, and national health policy. In addition to its research mission, CAPAS is committed to developing the next generation of investigators in population aging and dementia research. Through pilot project funding, interdisciplinary mentorship, educational seminars, collaborative workshops, and research training opportunities, the Center supports early-career investigators pursuing research at the intersection of aging, dementia, and population health. Trainees benefit from access to nationally recognized experts in aging research, diverse population datasets, and collaborative opportunities spanning basic science, clinical research, epidemiology, and social science. These activities complement the Barshop Institute's NIH-funded Biology of Aging Training Program (T32) and foster a highly collaborative environment for training future leaders in Alzheimer's disease and aging research.
=== Systems biology === Advances in quantitative proteomics would clearly enable more in-depth analysis of cellular systems. Another research frontier is the analysis of single cells, and protein covariation across single cells which reflects biological processes such as protein complex formation, immune functions, as well as cell cycle and priming of cancer cells for drug resistance Biological systems are subject to a variety of perturbations (cell cycle, cellular differentiation, carcinogenesis, environment (biophysical), etc.). Transcriptional and translational responses to these perturbations results in functional changes to the proteome implicated in response to the stimulus. Therefore, describing and quantifying proteome-wide changes in protein abundance is crucial towards understanding biological phenomenon more holistically, on the level of the entire system. In this way, proteomics can be seen as complementary to genomics, transcriptomics, epigenomics, metabolomics, and other -omics approaches in integrative analyses attempting to define biological phenotypes more comprehensively. As an example, The Cancer Proteome Atlas provides quantitative protein expression data for ~200 proteins in over 4,000 tumor samples with matched transcriptomic and genomic data from The Cancer Genome Atlas. Similar datasets in other cell types, tissue types, and species, particularly using deep shotgun mass spectrometry, will be an immensely important resource for research in fields like cancer biology, developmental and stem cell biology, medicine, and evolutionary biology.
A defensive reaction of the skin is the formation of a light callus, the skin's own sun protection, which corresponds to a protection factor of about 5. At the same time, the production of brown skin pigments (melanin) in the corresponding cells (melanocytes) is stimulated. A solar control film is usually a film made of polyethylene terephthalate (PET) that is applied to windows to reduce the light and heat from the sun's rays. The film filters UV-A and UV-B radiation. Polyethylene terephthalate goes back to an invention by the two Englishmen John Rex Whinfield (1902-1966) and James Tennant Dickson in 1941.
=== Addison's Disease === Corticotropic cells can also be the cause of Addison's disease in some instances. Addison's disease is characterized adrenal insufficiency, which is defined as the underproduction of glucocorticoids by the adrenal cortex. If the corticotropes underproduce ACTH this can result in secondary adrenal insufficiency, causing the adrenal glands to underproduce cortisol. This can be caused by tumors of the anterior pituitary or hypothalamus, inflammation, or surgery. This ultimately results in the underproduction of cortisol, which has many detrimental symptoms. Symptoms of Addison's disease include:
Sources: en.wikipedia.org
Conrad Elvehjem, the son of Norwegian emigrants to Wisconsin, was born in McFarland, Wisconsin. He progressed through the secondary schools and the University of Wisconsin, where he received his PhD in 1927 with mentor E.B. Hart for his studies of the importance of copper in iron-deficiency anemia. A National Research Council fellowship permitted a year at Cambridge University in England. Elvehjem began teaching in agricultural chemistry at the University of Wisconsin in 1923, and became a full professor in 1936. He became chairman of the biochemistry department in 1944 and dean of the graduate school in 1946, at 45 years of age. He served as dean of the graduate school until he became the university's 13th president in 1958. Picking up on the work of Joseph Goldberger, he found that nicotinic acid cured black tongue in dogs, an analogous disease to pellagra. In the previous year, Elvehjem and his colleague Carl J. Koehn had found that a filtrate factor from a liver extract could cure diet-induced pellagra in chicks. That filtrate extract was designated as the vitamin G fraction, after the late Goldberger. To confirm their findings in dogs, they induced black tongue in these animals with the Goldberger diet of yellow corn, before supplementing the diet with the vitamin G fraction. Elvehjem and his colleagues later were able to isolate and identify nicotinamide and nicotinic acid from vitamin G as the curative factors for black tongue in dogs.
=== Future Outlooks of DNA Legos === DNA Legos have promising applications in drug encapsulation and intracellular delivery. DNA nanoparticles are created to have reactive groups with two pegs in a singular direction and two holes in another . This structure allows the bricks to connect and create various shapes. The shapes of the bricks can become complex to encapsulate various drug molecules. These shapes have been applied in an attempt to improve cancer immunotherapies. For example, DNA Legos have been formed into a star shape with sticky ends to encapsulate doxorubicin. When mixed in solution the sticky ends rapidly join together forming an icosahedron shaped brick with the anticancer drug inside of this structure. Another study investigated cellular uptake of spherical nucleic acid bricks (SNAs). Through SNA and dendritic cell interactions, tumor cells are efficiently killed as the spherical brick shape allows for tunable subcellular trafficking and peptide retention. Thus, creating various shaped DNA brick nanoparticles may improve efficacy of immunotherapies by encapsulating drug cargo improving cell uptake. Before DNA Legos can have clinical applicability as a nanoparticle, they must be stabilized to ensure proper drug release. Previously, RNA bricks have been locked in place by magnesium. Utilizing magnesium to set the shape of RNA bricks via kissing interactions allows for easy tunability of structures. This idea is easily translatable to DNA thus creating a mechanism in which DNA Legos can be stabilized for clinical use.
Besides the potential newer effects as antibiotics or anti-cancers, P.arhizus has traditionally been used for wound healing and hemorragic disorders in places such as Italy and regions of Africa. Looking beyond the composition of P.arhizus, the species has a number of confirmed uses as well as theoretical potentials. A traditional use of the fungus is as a dyeing agent (hence "dyeball") of assorted textiles, producing a range of pigments varying in description from yellow to shades of brown. P.arhizus has also has been mentioned for its use in forestry and land restoration as a mycorrhizal agent for inoculation projects, and some online gardening websites mention its positive effects on plant performance.
Sources: en.wikipedia.org
==== Documentaries without words ==== Films in the documentary form without words have been made. Listen to Britain, directed by Humphrey Jennings and Stuart McAllister in 1942, is a wordless meditation on wartime Britain. From 1982, the Qatsi trilogy and the similar Baraka could be described as visual tone poems, with music related to the images, but no spoken content. Koyaanisqatsi (part of the Qatsi trilogy) consists primarily of slow motion and time-lapse photography of cities and many natural landscapes across the United States. Baraka tries to capture the great pulse of humanity as it flocks and swarms in daily activity and religious ceremonies. Bodysong was made in 2003 and won a British Independent Film Award for "Best British Documentary." The 2004 film Genesis shows animal and plant life in states of expansion, decay, sex, and death, with some, but little, narration.
== Physicochemical properties == Polyacrylamide is a polyolefin. It can be viewed as polyethylene with amide substituents on alternating carbons. Unlike various nylons, polyacrylamide is not a polyamide because the amide groups are not in the polymer backbone. Owing to the presence of the amide (CONH2) groups, alternating carbon atoms in the backbone are stereogenic (chiral). For this reason, polyacrylamide exists in atactic, syndiotactic, and isotactic forms, although this aspect is rarely discussed. The polymerization is initiated with radicals and is assumed to be stereorandom.
== History == There were suggestions in the scientific literature as early as 1956 that trans fats could cause an increase in coronary artery disease. Studies in the early 1990s brought renewed scrutiny and confirmation of the negative health impact of trans fats. In 1994, it was estimated that trans fats caused at least 20,000 deaths annually in the U.S. from heart disease. In the 1990s, activist organization Center for Science in the Public Interest (CSPI) called for reducing trans fats in foods, and later lobbied for them to be disclosed on product labels and menus. Several lawsuits were launched against high-visibility restaurants and food manufacturers with the objective of supporting a broader phase-out of trans fats. Mandatory food labeling was introduced in several countries and Denmark was first to mandate limits on industrially produced trans fats in 2004. In January 2007, faced with the prospect of an outright ban on the sale of their product, Crisco was reformulated to meet the U.S. Food and Drug Administration (FDA) definition of "zero grams trans fats per serving" (that is less than one gram per tablespoon, or up to 7% by weight; or less than 0.5 grams per serving size) by boosting the saturation and then diluting the resulting solid fat with unsaturated vegetable oils. Noting that elimination of industrially produced trans fat is feasible and achievable, the World Health Organization (WHO) has set a goal to make the world free from industrially produced trans fat by the end of 2023.
Another important piece of evidence is from detailed phylogenetic trees (i.e., "genealogic trees" of species) mapping out the proposed divisions and common ancestors of all living species. In 2010, Douglas L. Theobald published a statistical analysis of available genetic data, mapping them to phylogenetic trees, that gave "strong quantitative support, by a formal test, for the unity of life." Traditionally, these trees have been built using morphological methods, such as appearance, embryology, etc. Recently, it has been possible to construct these trees using molecular data, based on similarities and differences between genetic and protein sequences. All these methods produce essentially similar results, even though most genetic variation has no influence over external morphology. That phylogenetic trees based on different types of information agree with each other is strong evidence of a real underlying common descent.
Sources: en.wikipedia.org
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.
Naming for research peptides is not standardised, and suppliers sometimes apply the same label to different chain lengths. Certificates of analysis and mass data are the practical way to determine what a given lot contains.
The fragment commonly cited under this label is reported near 889 Da, and the parent protein near 4963 Da. Reported values shift with the exact sequence and with residual counter-ions or water in the sample.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.